{{Infobox company
| company_name = Bone Medical Ltd
| company_logo = 
| company_type = Listed Public Company
| foundation = 2002
| location = [[Perth]], [[Australia]].
| key_people = Peter Young (Chief Executive Officer)
Dr. [[Roger New]] PhD (Research)
Leon Ivory (non-executive director)
| area_served = Global
| industry = Biotechnology
| products = 
| revenue = 
| operating_income = 
| net_income = 
| num_employees = 
| predecessor = 
| parent = 
| subsid = 
| homepage = [http://www.bone-ltd.com/ Bone Limited]
| footnotes =
}}

'''Bone Medical''' is a small [[Perth]]-based [[biopharmaceutical]] company aiming to develop medicines for bone and joint disease. Located in [[Technology Park (Bentley)]], [[Perth]], it focuses on orally administered preparations for treatment of [[osteoporosis]] and [[arthritis]].<ref name=newissue>[http://www.asx.com.au/asxpdf/20121029/pdf/429rv3l5t0cr4n.pdf [[ASX]] media release: Share Issue]</ref><ref>{{cite web|url=http://www.ausbiotech.org/directory/details.asp?companyid={FCDD472B-E719-46D0-80F2-F8EA1853E6D1}&returntourl=%2Fdirectory%2Fsearch.asp%3Fpg%3D9 |title=Bone Medical Limited (BNE) |publisher=Ausbiotech.org |date= |accessdate=2012-08-13}}</ref> Since July 2007, its  non-executive independent director has been Prof. Peter Brooks.<ref>[http://www.reuters.com/finance/stocks/officerProfile?symbol=BNE.AX&officerId=1014505 Brooks, Peter: Brief Biography] at [[Thomson Reuters]]</ref>

==Research==
{{As of|2012|12}}, the company was utilising technologies under licence from Proxima Concepts Ltd of [[Jersey]], [[Channel Islands]],<ref>[http://www.asx.com.au/asxpdf/20121204/pdf/42bpvqk6lg283v.pdf Notice of change of interests of substantial holder] at ASX, 2 December 2012</ref> in two clinical-trial projects aimed at improving administration of hormone replacement.<ref name=newissue/>{{rp|p.2}} 

One explores use of oral [[calcitonin]] for treatment of bone disease including osteoporosis;<ref>[http://www.bone-ltd.com/bn002.htm Capsitonin™] at official website</ref> the other explores oral administration of [[parathyroid hormone]], a controlling agent for the maintenance of normal calcium levels in the blood. Substitution of the latter for injected parathyroid hormone would potentially enhance accessibility and patient acceptance.<ref>[http://www.bone-ltd.com/bn003.htm CaPTHymone™] at official website</ref>

==References==
{{reflist|2}}


{{Portal|Business|Western_Australia|Medicine}}

{{Business in Australia}}
{{Western_Australia}}

[[Category:Biotechnology companies of Australia]]
[[Category:Companies based in Perth, Western Australia]]